Oncology Deal Spree To Continue For AbbVie – Early Cancer Pipeline Outweighs Other Disease R&D
Cancer focused and charging forwards, AbbVie makes 2017 the year its pipeline will expand a little more. Scrip looks at the company’s growing oncology portfolio and what is yet to come and speaks to medical affairs head Bianca Wittig about challenges intertwined with oncology R&D.
You may also be interested in...
CEO says the idea of forming one company around Humira and its earnings and another around the R&D pipeline holds merit but he wants to wait to see the outcome of US tax reform, which could address some of AbbVie's issues.
New data position BCL-2 inhibitor Venclexta, partnered with Roche, for roles in multiple myeloma and acute myeloid leukemia, among other indications beyond chronic lymphocytic leukemia.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.